Sponsor or institution

Clinical trials and research at Shanghai Hengrui Pharmaceutical Co., Ltd.

• 20Clinical trials
• 1Country

Newest trials

All recruiting trials (20)

• Shrinkage-free combo in LS-SCLC: SHR-7787 plus SHR-1316

  This trial tests whether the combo of SHR-7787 and SHR-1316 can help adults with unresectable limited-stage small cell lung cancer after prior platinum-based chemo and radiation.

  Recruiting Phase 2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Jinan, Shandong · NCT07798947

• SHR-3836 in Relapsed or Refractory Multiple Myeloma

  This phase 1 study tests SHR-3836 in adults with relapsed or refractory multiple myeloma to see if it can be given safely and what effects it has.

  Recruiting Phase 1 Shanghai Hengrui Pharmaceutical Co., Ltd. · Suzhou, Jiangsu · NCT07490613

• HRS-4642 with chemotherapy and immunotherapy for advanced pancreatic cancer

  This study tries adding HRS-4642 to standard chemotherapy and/or an immune therapy to see if it helps people with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma.

  Recruiting Phase 1/2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07296341

• SHR-7787 combined with other anti-cancer drugs for malignant solid tumors

  This study will test whether giving SHR-7787 together with other anti-cancer medicines is safe and helps people with unresectable malignant solid tumors.

  Recruiting at 2 sites Phase 2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Wuhan, Hubei and 1 other locations · NCT07268040

• SHR-A2102 combined with other anti-cancer therapies around surgery for resectable non-small cell lung cancer

  This trial will test SHR-A2102 given with other anti-cancer drugs around the time of surgery in adults with resectable non-small cell lung cancer.

  Recruiting Phase 2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT07229729

• SHR-7367 combined with other anti-cancer agents for adults with advanced solid tumors.

  This trial will test whether SHR-7367 given with standard anti-cancer drugs is safe and shows early signs of benefit in adults with advanced solid tumors.

  Recruiting Phase 1/2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Tianjin, Tianjin Municipality · NCT07229586

• SHR-1501 plus adebrelimab for advanced or metastatic solid tumors

  This trial will test whether combining SHR-1501 and adebrelimab can shrink tumors or control disease in adults with advanced or metastatic solid tumors who have exhausted standard treatments.

  Recruiting Phase 1/2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT07073534

• Testing SHR-A2102 with other cancer treatments for advanced solid tumors

  This study is testing a new cancer treatment called SHR-A2102 combined with other therapies to see if it helps people with advanced solid tumors feel better and improve their outcomes.

  Recruiting Phase 2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Taiyuan, Shanxi · NCT06895928

• Comparing SHR-A2102 to standard therapies for advanced bladder cancer

  This study is testing a new injectable treatment called SHR-A2102 against standard therapies for people with advanced bladder cancer who have already tried other treatments.

  Recruiting Phase 3 Shanghai Hengrui Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT06738251

• Comparing SHR-A1904 to standard treatments for advanced gastric cancer

  This study is testing a new treatment called SHR-A1904 to see if it helps people with advanced stomach cancer live longer compared to standard therapies they might usually receive.

  Recruiting Phase 3 Shanghai Hengrui Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT06649292

• Evaluating SHR-A2102 with Antitumor Therapy for Advanced Urothelial Carcinoma

  This study is testing a new treatment called SHR-A2102 combined with other therapies to see if it can help patients with advanced urothelial carcinoma who haven't had success with standard treatments.

  Recruiting Phase 1/2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT06639347

• Evaluating SHR-7787 Injection for Advanced Solid Tumors

  This study is testing a new injection called SHR-7787 to see if it is safe and effective for people with advanced solid tumors that can't be removed by surgery.

  Recruiting Phase 1/2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06605222

• Combining SHR-A2102 and Adebrelimab for Advanced Lung Cancer

  This study is testing a new combination of two drugs, SHR-A2102 and Adebrelimab, to see if they can help people with advanced lung cancer feel better and improve their treatment outcomes.

  Recruiting Phase 1/2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT06512051

• SHR-9839 combined with other anti-cancer treatments for advanced solid tumors

  This trial will test whether adding the experimental drug SHR-9839 to other cancer treatments helps adults with advanced solid tumors tolerate therapy and shrink tumors.

  Recruiting at 2 sites Phase 1/2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Zhengzhou, Henan and 1 other locations · NCT06474455

• Evaluating SHR-A2102 for Advanced Solid Tumors

  This study is testing a new treatment called SHR-A2102 to see if it can help people with advanced solid tumors who haven't had success with other therapies.

  Recruiting Phase 1/2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT06417554

• Treatment for advanced solid tumors with CLDN18.2 expression

  This study is testing a new treatment called SHR-A1904 for people with advanced solid tumors that have a specific marker, to see if it works better than the usual chemotherapy and immunotherapy.

  Recruiting Phase 1 Shanghai Hengrui Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT06350006

• Treatment of intermediate and high-risk non-muscle invasive bladder cancer with SHR-2005

  This study is testing a new treatment called SHR-2005 for people with intermediate and high-risk non-muscle invasive bladder cancer to see if it is safe and effective.

  Recruiting Phase 1 Shanghai Hengrui Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06108492

• Testing SHR-9839 injections for adults with advanced solid tumors

  This will test SHR-9839 injections to see if they are safe and show anti-tumor activity in adults with unresectable or metastatic solid tumors who have exhausted or lack standard treatment options.

  Recruiting Phase 1 Shanghai Hengrui Pharmaceutical Co., Ltd. · Hangzhou, Zhejiang · NCT05836948

• Phase I SHR-A2102 for advanced solid tumors

  This Phase I test gives SHR-A2102 to adults with advanced solid tumors to find a safe dose and see how safe it is and how the body processes the drug.

  Recruiting Phase 1 Shanghai Hengrui Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT05701709

• Evaluating SHR-1501 for treating high-risk NMIBC

  This study is testing a new treatment called SHR-1501, alone and with other medications, to see if it can safely help people with high-risk non-muscle invasive bladder cancer.

  Recruiting Phase 1/2 Shanghai Hengrui Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT05410730

Quick answers

How many clinical trials run by Shanghai Hengrui Pharmaceutical Co., Ltd. are recruiting right now?

20, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 9, Phase 1: 5, Phase 2: 4, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →